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Carbamazepine (CBZ) has been extensively used in the treatment of epilepsy, as well as in the
treatment of neuropathic pain and affective disorders. However, the mechanisms of action of
this drug are not completely elucidated and are still a matter of debate. Since CBZ is not very
effective in some epileptic patients and may cause several adverse effects, several antiepileptic
drugs have been developed by structural variation of CBZ, such as oxcarbazepine (OXC), which
is used in the treatment of epilepsy since 1990. (S)-(2)-10-acetoxy-10,11-dihydro-5H-dibenz
[b,f ]azepine-5-carboxamide (BIA 2-093) and 10,11-dihydro-10-hydroxyimino-5H-dibenz[b,f ]
azepine-5-carboxamide (BIA 2-024), which were recently developed by BIAL, are new puta-
tive antiepileptic drugs, with some improved properties. In this review, we will focus on the
mechanisms of action of CBZ and its derivatives, OXC, BIA 2-093 and BIA 2-024. The avail-
able data indicate that the anticonvulsant efficacy of these AEDs is mainly due to the inhibition
of sodium channel activity.
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phenobarbital, phenytoin, carbamazepine (CBZ) and
valproic acid. CBZ (5H-dibenz[b,f ]azepine-5-carbox-
amide) was introduced in the early sixties, and has
become the most frequently prescribed drug for the
treatment of several forms of epilepsy. CBZ is also
used in the treatment of neuropathic pain (1) and in
psychiatric disorders (2).
CBZ is an iminodibenzyl derivative, structurally
similar to the tricyclic antidepressants (Fig. 1). This
drug is extensively metabolized in the liver, and only
1% of the administered dose is excreted in the un-
changed form. The main oxidative pathway involves
the formation of an active metabolite, carbamazepine-
10,11-epoxide (3), which possesses anticonvulsant
properties similar to those of CBZ.
Overall, the treatment with CBZ is effective and
safe. However, approximately 30–40% of epileptic pa-
tients do not respond very well to the treatment (4) and
CBZ may cause some adverse effects. For example,
INTRODUCTION
Epilepsy is one of the most common neurological
disorders, affecting about 50 million people world-
wide. Phenobarbital, one of the first compounds uti-
lized in the treatment of epilepsy, was introduced in
1912. Since then, several antiepileptic drugs (AEDs)
have been developed, but only some of them have
become established. It is estimated that the majority
of epileptic patients are treated with only four drugs:
acute CBZ toxicity at therapeutic doses affects central
nervous system and gastrointestinal system, causing se-
dation, ataxia, dizziness, nausea, vomiting, constipation
and diarrhea. Long-term treatment with CBZ may mod-
ify plasma lipids, changes the concentration of sex hor-
mones, produces hyponatremia, increases appetite and
causes weight-gain, reduces the number of white blood
cells and induces several allergic reactions (2). CBZ
may also interact with other AEDs or with other drugs,
such as antibiotics, contraceptives and calcium channel
blockers (5,6), and induces its own hepatic metabolism
and that of a variety of other drugs. CBZ may also in-
duce multiple cytochrome P450 subfamilies (7).
In recent years, several AEDs have been devel-
oped to improve the treatment of seizures resistant to
treatment with currently available anticonvulsants, and
to improve the tolerability and safety of AEDs. The
anticonvulsant efficacy of these new drugs, such as viga-
batrin, lamotrigin, gabapentin, felbamate and oxcar-
bazepine (OXC), does not seem to be greater than that
of first generation drugs, but they are better tolerated
and have lower adverse effects and interactions (8).
Oxcarbazepine (10,11-dihydro-10-oxo-carbamaze-
pine) (Fig. 1) was developed by structural variation
of CBZ, and was introduced in 1990 (9). There exist
striking species differences in the metabolism of OXC.
In rats and dogs, the parent compound persists in fairly
high concentrations, whereas in humans and other pri-
mates OXC is almost immediately converted to the
main active metabolite, 10,11-dihydro-10-hydroxy-5H-
dibenz[b,f ]azepine-5-carboxamide (10-hydroxycarba-
zepine; 10-OH-CBZ). In these cases, it is considered a
prodrug. OXC and CBZ have a comparable anti-
convulsant efficacy, but OXC has the advantage of a
low incidence of allergic reactions, enzyme induction
and side effects (10,11). The main adverse effect of
OXC is hyponatriemia, which may occur more fre-
quently than with CBZ, but it is rarely symptomatic (8).
In recent years, new drugs with anticonvulsant
properties and structural features similar to established
AEDs have been developed. (S)-(2)-10-acetoxy-
10,11-dihydro-5H-dibenz[b,f ]azepine-5-carboxamide
(BIA 2-093) and 10,11-dihydro-10-hydroxyimino-5H-
dibenz[b,f ]azepine-5-carboxamide (BIA 2-024) are new
putative AEDs (Fig. 1), developed by BIAL (Portela &
Co., Portugal), chemically related to CBZ and OXC,
but specifically designed to circumvent their further
degradation to toxic metabolites. BIA 2-093 and BIA
2-024 were found to be effective anticonvulsants. Both
compounds exerted protective effects against seizures
induced by maximal electroshock and were also effec-
tive in protecting rats against convulsions induced by
metrazol, having greater or similar anticonvulsant po-
tency than that of reference compounds, CBZ or OXC
(12,13).
It is widely accepted that the majority of AEDs
act by more than one mechanism. This review focuses
on the mechanisms of action of CBZ and of its deriv-
atives, OXC, BIA 2-093 and BIA 2-024.
Carbamazepine. A large body of evidence indi-
cates that CBZ may interact with different types of
channels and receptors, as summarized in Table I. The
main target of CBZ are voltage-dependent sodium
channels. CBZ and carbamazepine-epoxide reduce the
frequency of sustained repetitive firing of action po-
tentials in cultured mammalian central neurons. CBZ
inhibits high frequency but not low frequency firing
(15,16). Such voltage- or frequency-dependent block
is ascribed to a voltage-dependent inhibitory effect on
voltage-gated sodium channels. It has been shown that
the inhibition of sodium currents in cultured neuro-
blastoma cells and in small cells from adult rat dorsal
root ganglia is more potent at more depolarized poten-
tials (17,18). Therefore, it appears that the inactivated
conformation of sodium channels has a higher affinity
to CBZ than the resting conformation, and that the
drug can prevent the transition of the inactivated chan-
nels to the closed state (19,20).
Several biochemical experiments corroborate the
electrophysiological observations. Thus, it was demon-
122 Ambrósio, Soares-da-Silva, Carvalho, and Carvalho
Fig. 1. Structural formulae of carbamazepine (CBZ), oxcarbazepine
(OXC) and of two dibenz[b,f ]azepine-5-carboxamide derivatives,
BIA 2-093 and BIA 2-024.
strated that CBZ blocks [3H]batrachotoxin or [3H]ba-
trachotoxinin A 20-a-benzoate binding to synapto-
somes. This effect is more evident at depolarizing
conditions (12,21). CBZ also inhibits the 22Na1 influx
stimulated by batrachotoxin in cultured neuroblastoma
cells and rat brain synaptosomes (22) and stimulated by
veratridine in cortical synaptosomes (12). The site of
interaction of several voltage-dependent blockers is on
the cytosolic side of the alpha subunit of Na1 channels,
probably within the ion-conducting pathway, as shown
by site-directed mutagenesis (23).
An increasing number of findings indicate that
CBZ has also calcium antagonistic properties. A de-
cade ago, Elliot proposed that the efficacy of CBZ in
the treatment of seizures could be due to a frequency-
dependent block of sodium currents and a block of
calcium currents (15). Such calcium antagonistic prop-
erties would explain the similarities in the depressant
action of CBZ and organic calcium antagonists on
epileptic paroxysmal depolarizations (24,25). Indeed,
CBZ reversibly suppresses the calcium-dependent
components of action potentials and markedly reduces
the calcium currents, presumably L-type, in cultured
rat sensory spinal ganglion cells (26,27). In cultured
bovine adrenal medullary cells, CBZ and CBZ-10,11-
epoxide inhibit the secretion of catecholamines by in-
terfering with N-type voltage-sensitive calcium channels
(28,29). Schumacher et al. (30) also demonstrated that
CBZ produces a reversible, concentration-dependent
inhibition of high voltage-activated calcium currents,
without affecting voltage-dependent activation, in hu-
man hippocampal granule cells. More recently, we re-
ported that CBZ inhibits L-type calcium channels in
cultured rat hippocampal neurons stimulated with glu-
tamate receptor agonists (31). These findings clearly
indicate that CBZ has calcium antagonistic properties.
However, it is important to mention that the effects of
CBZ were not significant at therapeutic serum levels
of CBZ (17–51 mM) in some studies (15,30,31). More-
over, CBZ did not inhibit calcium currents in rat cor-
tical (32) and human cortical neurons (33). In human
neuroblastoma cells, CBZ had little effect at concen-
Mechanisms of Action of Carbamazepine and Derivatives 123
Table I. Mechanisms of Action of Carbamazepine and Its Derivatives
BIA 2-024
and
CBZ OXC BIA 2-093 References
Voltage-gated Inhibition Inhibition Inhibition 12, 17–22, 94–97,
Na1 channels 103, 105, 106
Voltage-gated Inhibition Inhibition No effect 15, 24–31, 35, 98
Ca21 channels
Voltage-gated K1 Potentiation Potentiation NDa 32, 36–41, 95
channels Inhibition
No effect
Adenosine A1 receptor A1 receptor ND 42–44, 47, 48, 99
receptors antagonism antagonism
A2 receptor
antagonism
A2 agonism
Serotonergic Increase of ND ND 51–53
system extracellular
serotonin
concentration
Dopaminergic Increase of Increase of ND 48, 59–62, 101
system dopaminergic dopaminergic
transmission transmission
Glutamergic Inhibition of Inhibition of Inhibition of 35, 55, 65–69
system glutamate release glutamate release glutamate release
Peripheral-type Interaction with ND ND 78–80
benzodiazepine PBRs
receptors (PBRs)
cAMP Decrease of basal ND ND 44, 85, 92
and stimulated
cAMP level
a ND, not determined.
trations that are therapeutically relevant (34). We also
found that CBZ does not affect the calcium channels
coupled to the exocytotic release of glutamate, in hippo-
campal nerve terminals (35). Therefore, it is not clear
whether the anticonvulsant efficacy of CBZ may be
also due to the modulation of calcium currents.
The effects of CBZ on K1 channels have also been
investigated. Olpe et al. (36) found that the depressant
effect of CBZ is attenuated by barium chloride and
4-aminopyridine, two potassium-channel blockers,
suggesting that CBZ may interfere with potassium
fluxes. Indeed, CBZ enhances outward, voltage-de-
pendent K1 currents in rat neocortical cells (32). How-
ever, CBZ also blocks delayed K1 currents (37) and
calcium-activated K1 currents (38). It was also re-
ported that CBZ does not affect K1 currents
(37,39–41). Taking this into account, it is not clear
whether the modulation of K1 channels contribute to
the anticonvulsant efficacy of CBZ.
It has been proposed that the anticonvulsant, as
well as the therapeutic and prophylactic effects of
CBZ in affective psychoses may, in part, be related to
the potent interaction of CBZ with adenosine-binding
sites in the brain. Indeed, several reports have demon-
strated that CBZ acts as an antagonist at adenosine A1
receptors (42–44). Application or chronic treatment
with CBZ induces up-regulation of adenosine A1 re-
ceptors in astrocytes (45) and rats (46), respectively.
Although previous results also indicate that CBZ may
act as an adenosine A2 receptor antagonist (47), Van
Calker et al. (44) demonstrated that CBZ is not an
antagonist of high-affinity A2a adenosine receptors.
Conversely, it was reported that CBZ is an adenosine
A2 receptor agonist (48). These findings suggest that
the effects of CBZ may also result from effects on both
adenosine A1 and A2 receptors. However, binding stud-
ies and the observation that a specific adenosine A1 re-
ceptor antagonist have no effect on the anticonvulsant
action of CBZ suggest that the alteration of adenosine
A1 receptor activity is not an important mechanism for
the anticonvulsant efficacy of CBZ (43,49,50).
A large body of evidence indicates that serotonin
has anticonvulsant properties in several seizure models.
CBZ causes large increases in extracellular serotonin
concentration and produces dose-related anticonvulsant
effects in both genetically epilepsy-prone rats (GEPRs)
and non-epileptic Sprague-Dawley rats (51–53). The
effects of CBZ were not prevented by tetrodotoxin and
by removal of calcium, suggesting that the enhance-
ment of serotonin release is not dependent on sodium
channel function and does not take place by exocyto-
sis (53). Moreover, Dailey et al. (54) also found that
CBZ induces the release of serotonin by a mechanism
that does not involve the serotonin transporter. It was
also demonstrated that therapeutic concentrations of
CBZ enhance serotonin turnover and transmission in
hippocampus (55). Therefore, it appears that serotonin
release may play a role in the anticonvulsant efficacy of
CBZ, as well as in the efficacy of CBZ in the treatment
of affective disorders.
The inhibition of serotonin uptake by CBZ was
also recently reported (56). This effect probably reflects
an affinity of CBZ for biogenic amine transporters.
However, binding studies demonstrated that CBZ does
not displace serotonergic radioligands, indicating that
the anticonvulsant effect of CBZ cannot be attributed to
a direct action at the serotonin recognition site (57).
Some data also suggest that CBZ may alter dopa-
mine function (58). CBZ enhances dopamine release
and turnover and causes differential alterations of mono-
amine levels in discrete brain regions (48,59–62).
These effects on dopaminergic system may be, at least
partially, involved in the mechanisms of action of
CBZ. However, indirect clinical evidence, such as lack
of parkinsonian side effects and tardive dyskinesia,
suggests that CBZ does not act by blocking dopamine
receptors (63).
It is widely accepted that glutamate is involved in
the initiation and propagation of seizures. A large
body of evidence established that NMDA and non-
NMDA receptors play a crucial role in seizure activity
and are potential targets for AEDs (64). Therefore, the
inhibition of either glutamate release or ionotropic
glutamate receptors might contribute to the efficacy
of anticonvulsants against epileptic seizures. CBZ re-
duces the release of glutamate evoked by potassium,
veratrine or veratridine from hippocampus, cerebral
cortex or brain slices (55,65–68), presumably due to
its sodium channel blocking properties. Moreover,
CBZ inhibits the release of glutamate from cortical
and hippocampal synaptosomes evoked by veratridine
or 4-aminopyridine, but not that evoked by KCl, indi-
cating that CBZ blocks presynaptic sodium channels,
but not calcium channels (35,69). This group of results
suggests that the inhibition of glutamate release may
contribute, at least partially, to the anticonvulsant
properties of CBZ. However, Waldemeier et al. (67,68)
suggested that it is uncertain whether the effects of
CBZ are relevant at anticonvulsant doses in vivo, since
inhibition of electrically-induced glutamate release
requires much higher concentrations of CBZ than the
release elicited by veratrine.
Previous reports indicate that CBZ may also in-
teract with the function of ionotropic glutamate recep-
tors. Indeed, it was demonstrated that CBZ blocks
NMDA-induced currents in cultured spinal cord neu-
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rons (70), prevents the elevation of [Ca21]i induced by
kainate (71), inhibits NMDA-induced depolarizations
in cortical wedges (72), prevents convulsions pro-
duced by administration of NMDA (73), inhibits
NMDA-evoked calcium influx in rat cerebellar gran-
ule cells, particularly under depolarizing conditions,
by a mechanism that is independent of the NMDA and
glycine recognition sites (74), and attenuates responses
to AMPA in rat cortical wedges (75). However, Phillips
et al. (75) demonstrated that the anticonvulsant effects
of CBZ are unlikely to involve antagonism of ionotropic
glutamate receptors. Furthermore, Grant et al. (76)
showed that CBZ is inactive in displacing binding
to [3H]dizocilpine, a selective non-competitive NMDA
antagonist, at concentrations substantially higher than
the therapeutic brain levels. We recently found, in hip-
pocampal neurons, that ionotropic glutamate receptors
are not directly affected by CBZ, and that the neuro-
toxic effect caused by CBZ is not prevented by NMDA
and AMPA receptor antagonists (77).
Experimental evidence has suggested that “pe-
ripheral-type” benzodiazepine receptors (PBRs) may
play a role in epilepsy and antiepileptic drug action,
and anticonvulsant drugs, such as CBZ, may exert
some of their effects through PBRs. Indeed, Maran-
gos et al. (78) showed for the first time that CBZ
interacts with PBRs, labeled with [3H]Ro 5-4864 (48-
chlorodiazepam), in rat brain membranes. An interac-
tion of CBZ with PBRs was also observed in primary
cultures of astrocytes (79). In addition, it was shown
that Ro 5- 4864 blocks the anticonvulsant effect of
CBZ on amygdala-kindled seizures in rats (80), and
that chronic CBZ treatment up-regulates the binding of
[3H]PK 11195, an antagonist of PBRs, to platelets of
epileptic patients (81). Since PBRs are also present in
lymphocytes, some immunological alterations caused
by CBZ treatment may be due to its interaction with
these receptors (82). This group of findings clearly in-
dicates that CBZ interacts with PBRs at therapeuti-
cally relevant concentrations. However, there is no
clear evidence showing that this interaction con-
tributes to the anticonvulsant effects of CBZ. It has
been postulated that abnormal increases in brain cyclic
AMP (cAMP) may play a role in the pathophysiology
of seizure disorders (83) and bipolar affective disor-
ders (84). Twenty five years ago, it was reported that
CBZ decreases the basal cAMP levels in cerebrospinal
fluid (CSF) of rabbits, and partly inhibits the rise in
cAMP after electrically-induced convulsions, suggest-
ing the involvement of cAMP in epileptic discharge
and in the mechanism of action of CBZ (85). After
that, it was also demonstrated that CBZ depresses
basal levels of cAMP in cerebral cortex and cere-
bellum (86), inhibits cAMP accumulation induced by
ouabain, norepinephrine, veratridine or adenosine, in
rat and mice cortex slices (44,86–89), and prevents
pentylenetetrazol-induced rise in cyclic AMP (90). It
was also reported that CBZ decreases the levels of
cAMP in CSF of manic patients (91). More recently,
Chen et al. (92) demonstrated that CBZ inhibits both
basal and forskolin-stimulated cAMP production in
C6 cells. The molecular mechanisms by which CBZ
causes this inhibitory effect are not completely clari-
fied. However, the results suggest that CBZ inhibits
the activity of adenylyl cyclase (AC), as well as the
downstream pathways of AC activation. In addition to
these effects on the cAMP system, it was recently
shown that NO-mediated mechanisms might be also
involved in the anticonvulsant actions of CBZ (93).
In conclusion, it is clear that CBZ does not act by
a single mechanism (Table 1). The therapeutic use of
CBZ in several disorders (epilepsy, mood disorders
and neuropathic pain) and the findings that CBZ may
act at different levels (channels, receptors and sig-
nalling pathways) clearly indicates that there is no sin-
gle cellular action of CBZ. However, for a particular
situation, it remains to be elucidated which mecha-
nisms are involved and which is the contribution of
each mechanism for the therapeutic effect of CBZ.
Oxcarbazepine. Much evidence indicates that
OXC and its monohydroxy derivative, 10-OH-CBZ,
may act on several ion channels and receptors. Indeed,
since the chemical structure of OXC is similar to that of
CBZ, the mechanisms of action may be similar. OXC
and 10-OH-CBZ inhibit sustained, high frequency,
repetitive firing of cultured spinal cord neurons due to
an inhibitory effect on voltage-dependent sodium chan-
nels. This effect was found to be voltage- and fre-
quency-dependent (94–97). Neurochemical studies also
showed that OXC binds to sodium channels and modu-
lates sodium entry in cortical synaptosomes (12).
Concerning a possible effect of OXC on Ca21
channels, it was demonstrated that the active metabo-
lite of OXC, 10-OH-CBZ, dose-dependently reduces
high-voltage-activated Ca21 channels evoked by mem-
brane depolarization in isolated cortical and striatal
neurons, but dihydropyridine-sensitive channels are
not involved (98). Such as in the case of CBZ, OXC
does not affect presynaptic Ca21 channels coupled to
the exocytotic release of glutamate in hippocampal
synaptosomes (35).
The blockade of penicillin-induced bursts may be
used as a measure of antiepileptic efficacy through an
effect on potassium channels. 10-OH-CBZ was shown
to reduce the frequency of penicillin-induced epilepti-
form discharges in hippocampal slices, this effect
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being antagonized by 4-aminopyridine, a potassium
channel blocker (95). Thus, it appears that 10-OH-
CBZ acts on potassium channels involved in the gen-
eration of burst discharges.
Similarly to CBZ, OXC may also act as an antag-
onist of adenosine A1 receptors. Deckert et al. (99)
demonstrated that OXC displaces [3H]DPCPX in human
hippocampus. It was also shown that OXC inhibits
[3H]-L-phenylisopropyladenosine and [3H]-N-ethyl-
carboxamidoadenosine binding to adenosine A1 and
A2 receptors, respectively, at therapeutic plasma levels
(100), suggesting that the anticonvulsive effects of
OXC may be due to an action on adenosine A1 and A2
receptors.
Since CBZ possesses a dopaminergic effect, and
OXC exhibits an antidepressive-like effect in the
learned helplessness and forced swimming test, Joca
et al. (101) evaluated whether the antidepressive effect
of OXC could be mediated by dopaminergic system,
and the results obtained suggest that OXC can enhance
dopaminergic transmission.
We recently found that OXC inhibits the evoked
release of endogenous glutamate from hippocampal
nerve terminals, this effect being mediated by the in-
hibition of voltage-sensitive sodium channels (35), but
it is uncertain whether this inhibitory effect on gluta-
mate release also contributes to the anticonvulsant
effects of OXC. In addition, we also found that the ac-
tivation of ionotropic glutamate receptors is not af-
fected by OXC (102).
To our knowledge, there are no reports related
with possible effects of OXC on serotonergic neurons,
“peripheral-type” benzodiazepine receptors, cAMP sys-
tem and NO-mediated mechanisms. Although OXC
may also affect these systems, it is currently accepted,
as in the case of CBZ, that the main mechanism of ac-
tion of this drug is the inhibition of voltage-dependent
sodium channels.
BIA 2-093 and BIA 2-024. BIA 2-093 and BIA
2-024 were recently found to be effective anticonvul-
sants. Both compounds conferred a dose-dependent
protection against convulsions induced by maximal
electroshock and metrazol (12,13,103). Though chem-
ically related to CBZ and OXC, BIA 2-093 and BIA
2-024 were specifically designed to achieve an im-
provement in antiepileptic efficacy by circumvention
of degradation to toxic metabolites, such as epoxides,
and the avoidance of enanteomeric impurity and un-
necessary production of enantiomers or diastereoiso-
mers of metabolites and conjugates. In fact, OXC
gives origin to both the S(1)- and R(2) enantiomer of
the 10-OH-CBZ, which are further converted to the
inactive trans-diol metabolite (104). In contrast, BIA
2-093 leads to an enantiomerically pure metabolism,
originating the long lasting S(1)-10-OH-CBZ, due to
its reduced propensity to originate the inactive trans-
diol metabolite (104). The major metabolite of BIA
2-024 is the inactive BIA 2-254 (10,11-dihydro-10-
nitro-5H-dibenz[b,f ]azepine-5-carboxamide), which
implies a not very common oxidation of an oxime de-
rivative to the corresponding nitro-compound (103).
BIA 2-093 and BIA 2-024, like CBZ, displace [3H]-
batrachotoxinin A 20-a benzoate binding to rat corti-
cal synaptosomes, indicating that both drugs interact
with receptor site 2 of voltage-dependent sodium chan-
nels in a competitive manner (12,103,105). BIA 2-093
inhibits, in a concentration-dependent manner, the up-
take of 22Na1 in the same preparation, in both cases
with higher potency than that of CBZ and OXC (12,
105). More recently, BIA 2-093, like CBZ, was found
to inhibit Na1 currents in the mouse neuroblastoma
cell line N1E-115, in a voltage-dependent way by an
interaction predominantly with the inactivated state of
the channel (106). Over the range of neuronal resting
membrane potentials likely to be encountered in the
brain in situ (270 to 290 mV), BIA 2-093 displayed
a similar inhibitory potency to CBZ. The potency of
inhibition was highly sensitive to holding potential, in-
creasing with depolarization. Holding the membrane
potential at a less negative voltage is known to in-
crease the proportion of channels in the slow inacti-
vated state. The voltage dependence suggests that BIA
2-093 has a much higher affinity for the inactivated
state of the channel compared with the resting state
(106). The affinity of BIA 2-093 for resting Na1 chan-
nels (KR 5 3315 mM) was about 3-fold lower than that
of CBZ (KR 5 984 mM). The affinity of BIA 2-093 for
inactivated sodium channels (Ki 5 99.9 mM) was
about 2-fold lower than that of CBZ (Ki 5 47.8 mM).
In the therapeutic context, a higher KR compared to a
Ki for a compound would indicate a functional selec-
tivity for rapidly firing (“epileptic”) neurons over neu-
rons displaying normal activity (106).
We also found that BIA 2-024 and BIA 2-093 in-
hibit the release of endogenous glutamate evoked by
4-aminopyridine or veratridine in a concentration-
dependent manner, in hippocampal synaptosomes, due
to inhibition of voltage-sensitive sodium channels
(35), although with lower potency than CBZ and OXC.
Contrarily, it was shown that BIA 2-093 is more po-
tent than CBZ and OXC at inhibiting the release of
glutamate induced by veratrine from striatal slices
(107). Moreover, CBZ, OXC and BIA 2-093, at the
minimal effective dose in the maximal electroshock
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test, failed to inhibit veratridine-induced release of as-
partate and glutamate (108). Therefore, it is not clear
whether the inhibition of glutamate release may con-
tribute to the anticonvulsant effects of these AEDs. We
recently also found that BIA 2-024 and BIA 2-093 do
not affect voltage-sensitive calcium channels and iono-
tropic glutamate receptors (35,102).
In contrast to CBZ and OXC, BIA 2-093 and BIA
2-024 were found to be less effective in producing
neurological impairment, having the highest protective
index among other dibenz[b,f ]azepine-5-carboxamide
derivatives (12,103). We also found that BIA 2-024
and BIA 2-093 are less toxic to hippocampal neurons
than CBZ and OXC. Surprisingly, OXC was even more
toxic than CBZ (77). These characteristics indicate that
BIA 2-093 and BIA 2-024 may be useful in man for the
treatment of epilepsy, as well as for some other nervous
system disorders, such as trigeminal neuralgia and af-
fective disorders.
Concluding Remarks. This review has focused on
the mechanisms of action of CBZ and its derivatives,
OXC, BIA 2-093 and BIA 2-024 (Table I). All 4 drugs
inhibit sodium channel activity, and this may be the
main mechanism of their anticonvulsant effects. Volt-
age-gated calcium channels were inhibited by CBZ
and OXC, although perhaps not at therapeutically rel-
evant concentrations, but not by BIA 2-093 and BIA
2-024. Accordingly, this effect may be not significant
for the anticonvulsant activity of these drugs. CBZ and
its derivatives inhibited glutamate release, but the cor-
relation between a decreased glutamate release and the
anticonvulsant activity of these drugs is uncertain.
Both CBZ and OXZ antagonized the A1 adenosine re-
ceptor, increased dopaminergic transmission and po-
tentiated voltage-gated potassium channels, but the
possible effects of BIA 2-093 and BIA 2-024 on these
parameters are unknown. A CBZ-mediated increase in
extracellular serotonin concentration, an interaction of
CBZ with peripheral-type benzodiazepine receptors,
and a decrease in basal and stimulated level of cAMP
may also be of importance for the anticonvulsant ac-
tion of CBZ, but it remains to be studied whether
OXZ, BIA 2-093 and BIA 2-024 exert similar effects.
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